Journal of Asthma最新文献

{"title":"Montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: Cost-utility analysis.","authors":"Jefferson Antonio Buendía, Diana Guerrero Patino, Juan Antonio Buendia Sanchez","doi":"10.1080/02770903.2025.2546348","DOIUrl":"https://doi.org/10.1080/02770903.2025.2546348","url":null,"abstract":"<p><strong>Introduction: </strong>The treatment of cough variant asthma is the same as for asthma in general. Recent evidence suggests montelukast (Mon) + fluticasone propionate (Flu) reduced cough recurrence regarding Flu in monotherapy. For health insurers whether this extra benefit offered by this combination of Flu is compensated by this additional cost compared to monotherapy with Flu. This study aims to evaluate the cost-utility of Montelukast (Mon) and Fluticasone Propionate (Flu) versus Flu monotherapy in children with Cough variant asthma in Colombia.</p><p><strong>Materials and methods: </strong>We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with cough variant asthma, reflecting the typical clinical profile in Colombia .A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with cough variant asthma. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used quality-adjusted life years (QALYs) and costs from a third-payer perspective over a 5-year time horizon.</p><p><strong>Results: </strong>The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs USD 5,180). The cost of Montelukast has the greatest influence on cost effectiveness, if the cost per dose of montelukast 5mg is less than US$0.034, the combination of Mon and Flu will be cost-effective at WTP of US$5180.</p><p><strong>Conclusion: </strong>The combination of Montelukast and Fluticasone Propionate is not cost-effective for the management of cough variant asthma in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Montelukast and further optimizing its clinical use.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction between secondhand smoke exposure and IL-17 gene polymorphism in pediatric asthma.","authors":"Berrak Oztosun, Azer Kilic Baskan, Aysel Kalayci, Deniz Ozceker, Mehmet Seven, Haluk Cokugras, Ayse Ayzit Kilinc Sakalli","doi":"10.1080/02770903.2025.2539802","DOIUrl":"10.1080/02770903.2025.2539802","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a multifactorial disease affecting approximately 300 million people worldwide. Multiple genes, environmental risk factors, and their interactions have been associated with asthma. Smoking triggers an IL-17-mediated inflammatory response. The IL-17-related inflammatory response may differ between individuals, and this difference is associated with IL-17 polymorphisms.</p><p><strong>Objective: </strong>Our aim was to investigate the effect of IL-17 polymorphism and its interaction with secondhand smoke on pediatric asthma.</p><p><strong>Methods: </strong>The study comprised 100 pediatric asthma patients and 100 healthy children. Cotinine levels were analyzed to show SHS exposure (SHSe). A genetic study was conducted to reveal IL-17F(rs763780) and IL-17A (rs8193036, rs2275913) polymorphisms. The study participants were categorized into four groups based on the cotinine results: asthma with SHSe, asthma without SHSe, control with SHSe, and control without SHSe.</p><p><strong>Results: </strong>The median cotinine concentration was 11.06 ng/ml. Children with asthma had lower cotinine levels than healthy children (<i>p</i> < 0.001). Genotype distributions and allele frequencies of rs763780, rs8193036, and rs2275913 were compared among the four groups, and no significant differences were found.</p><p><strong>Conclusion: </strong>This study is the first to demonstrate the relationship between IL-17 polymorphisms and SHS interaction in childhood asthma. Neither the presence of IL-17 polymorphisms nor the interaction of these polymorphisms with SHS was found to be associated. The lower cotinine levels in asthmatic children suggest that parents are more susceptible to SHSe. Cotinine levels in our cohort were significantly greater than those found in developed countries. This demonstrates that exposure to SHS is still a serious environmental issue in our country.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Tailoring of a Peer-Administered Asthma Management Intervention for Urban Latino Middle School Children.","authors":"Daphne Koinis-Mitchell, Christina D'Angelo, Maria Teresa Coutinho, Sheryl J Kopel, Rebecca Noga, Heather Yoho, Luis Guzman, Sumera S Subzwari, Elizabeth L McQuaid, Ligia Chavez, Jean-Marie Bruzzese, Anna J Yeo, Glorisa Canino","doi":"10.1080/02770903.2025.2539807","DOIUrl":"https://doi.org/10.1080/02770903.2025.2539807","url":null,"abstract":"<p><p><b>Objective</b>: Children from Latino backgrounds face unique challenges in managing asthma. Barriers are compounded when children live in urban settings and are exposed to urban stressors (e.g., barriers to medication use, neighborhood stress). Asthma management in schools is often directly implicated. This study aims to address these gaps in care by developing a 4-session, peer-facilitated, culturally tailored asthma self-management group intervention in urban public-school settings. <b>Methods</b>: We developed and tested the ASMAS (<u>A</u>sthma <u>S</u>elf-<u>Ma</u>nagement in <u>S</u>chools) intervention, utilizing an iterative process guided by previous work and theoretical models. Feedback from focus groups was used to further tailor ASMAS. We enrolled 81 middle school students in a cross-site pilot randomized controlled trial (RCT) to evaluate the efficacy of ASMAS compared both to Attention Control and No-Treatment Control conditions. Outcomes included asthma control, asthma-related sleep disruption, school absences, asthma self-efficacy, and availability of rescue inhaler and asthma action plan (AAP) at school. <b>Results</b>: Compared to Attention Control participants, youth who received ASMAS had improved asthma outcomes over time (baseline to end-of-treatment) including asthma control (t = 2.1, <i>p</i><.05, d=.4, M_diff=1.5), asthma-related sleep disruptions (t=-.24, <i>p</i> <.05, d=-.4, M_diff=-3.6), school absences (d=-.2), asthma management self-efficacy (t = 2.3, <i>p</i> <.05, d=.4, M_diff=0.3) and rates of AAP (t = 1.8, <i>p</i> =.06; d=.3, M_diff=20%) and rescue inhalers availability (t = 2.0, <i>p</i> <.01, d=.7, M_diff=23%). Similar patterns were maintained at 4-month follow-up. <b>Conclusions</b>: Results demonstrate ASMAS' feasibility and highlight the potential benefits of the tailored asthma intervention. A full-scale RCT to evaluate ASMAS' effectiveness, implementation, and sustainability is warranted.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-16"},"PeriodicalIF":1.3,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and associated factors of pediatric uncontrolled asthma in Vietnam.","authors":"Ly Cong Tran, Phuong Minh Nguyen, Nghia Quang Bui, Chau Bao Vo, Giang Thanh Huynh Lam, Y Nhu Thi Nguyen, Thang Hoang Le, Duy-Truong Khac Le, My Hoang Le","doi":"10.1080/02770903.2025.2482988","DOIUrl":"10.1080/02770903.2025.2482988","url":null,"abstract":"<p><strong>Objective: </strong>Uncontrolled asthma profoundly affects quality of life and imposes a significant societal burden. However, reports on its prevalence and contributing factors in Vietnam remain limited. This study aimed to address this gap by investigating the prevalence and factors associated with uncontrolled asthma among children in Vietnam.</p><p><strong>Methods: </strong>An analytical cross-sectional study was conducted involving 344 pediatric asthma patients and their caregivers. The Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT) were used to assess asthma control in children aged 4-11 and 12-16 years, respectively. Data on patient, caregiver, and treatment characteristics were collected for analysis. Logistic regression analysis was employed to identify factors associated with uncontrolled asthma.</p><p><strong>Results: </strong>The prevalence of uncontrolled asthma was 40.1%. Factors significantly associated with uncontrolled asthma included previous admissions due to asthma (aOR = 2.80, 95% CI: 1.56-5.04, <i>p</i> < .001), inadequate caregiver knowledge (aOR = 2.86, 95% CI: 1.58-5.19, <i>p</i> < .001), and non-adherence to controller medication (aOR = 1.92, 95% CI: 1.07-3.48, <i>p</i> = .030).</p><p><strong>Conclusions: </strong>The prevalence of uncontrolled asthma in Vietnamese children is quite high. Previous admissions due to asthma, inadequate caregiver knowledge, and controller medication non-adherence were identified as significant factors associated with uncontrolled asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1389-1398"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of mepolizumab in adult patients with severe asthma with an eosinophilic phenotype from India: a Phase IV, open-label, single-arm, 24-week study (PRISM).","authors":"Priti Meshram, Venkata Nagarjuna Maturu, Rajesh Swarnakar, Pooja Deb, Disha Gupta, Samir Adsule, Rashmi Hegde","doi":"10.1080/02770903.2025.2475452","DOIUrl":"10.1080/02770903.2025.2475452","url":null,"abstract":"<p><strong>Objective: </strong>Existing mepolizumab trials have excluded patients with severe asthma with an eosinophilic phenotype (SAEP) from India. This study (NCT04276233) investigated the safety and effectiveness of mepolizumab in Indian adults with SAEP.</p><p><strong>Methods: </strong>Multi-center, open-label, single-arm, interventional study; patients received 100 mg mepolizumab subcutaneously every four weeks for 24 weeks. Primary endpoint: incidence of adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs). Secondary endpoints: clinically significant exacerbation (CSEs) frequency (including exacerbations requiring hospitalization); change from baseline to Week 24 in forced expiratory volume/second (FEV₁), peak expiratory flow (PEF), and Asthma Control Questionnaire (ACQ-5) scores.</p><p><strong>Results: </strong>Overall, 100 patients received ≥1 mepolizumab dose. Baseline characteristics: female, 51.0%; mean (standard deviation [SD]) age, 44.8 (12.0) years; mean (SD) body mass index, 24.4 (4.7) kg/m². On-treatment AEs and SAEs were reported by 18.0% and 3.0% of patients, respectively; regarding AESIs, 5.0% reported infection and 2.0% reported systemic reaction. One fatal event occurred (unrelated to mepolizumab). CSEs were reported by 8.0% of patients; 2.0% had an exacerbation requiring hospitalization. Least squares (LS) mean change (95% confidence interval) in pre- and post-bronchodilator FEV₁ and PEF by Week 24 was 0.081 L (-0.05, 0.21; <i>p</i> = 0.231), 0.055 L (-0.06, 0.17; <i>p</i> = 0.325), and 13.67 L/min (3.08, 24.25; <i>p</i> = 0.012), respectively. By Week 24, ACQ-5 scores had significantly improved (LS mean change [standard error]: -0.69 [0.121]; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Mepolizumab was well tolerated in Indian adults with SAEP and improved asthma control and health-related quality of life.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1313-1323"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma incidence, prevalence, and mortality in the United States and worldwide, 1990-2019: Findings from the Global Burden of Disease study.","authors":"Hamza Ashraf, Mahad Butt, Shanzay Akhtar, Aimen Nadeem, Rutaab Kareem, Haider Ashfaq, Zain Ali Nadeem, Maurish Fatima, Ali Ashraf, Jenish Bhandari","doi":"10.1080/02770903.2025.2482998","DOIUrl":"10.1080/02770903.2025.2482998","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is a serious global health issue, contributing to premature deaths and reduced quality of life.</p><p><strong>Objective: </strong>This study examines trends in the incidence, prevalence, and mortality of asthma in the US and globally from 1990 to 2019.</p><p><strong>Methods: </strong>Data from the Global Burden of Disease database were used to calculate age-standardized incidence (ASIR), prevalence (ASPR), and mortality (ASMR) rates per 100,000 individuals, stratified by gender. Joinpoint regression analysis determined annual percent changes (APCs), and average annual percentage changes (AAPCs) were calculated as weighted averages of these trends.</p><p><strong>Results: </strong>In the US, ASIR increased by 10.2%, rising from 1404.6 in 1990 to 1547.2 in 2019, with an overall AAPC of 0.33. Globally, ASIR decreased by 13%, declining from 580.1 to 504.3, with an overall AAPC of -0.46. ASPR in the US rose from 9374.0 to 10399.3, reflecting a 0.37% annual increase, whereas globally, ASPR dropped by 24.1%, decreasing from 4496.9 to 3415.5 with an overall AAPC of -0.91. Females consistently exhibited higher ASPR rates than males in both settings. US asthma mortality decreased by 50%, with ASMR dropping from 1.66 to 0.87 and an AAPC of -2.15. Globally, ASMR decreased by 51.3%, falling from 11.91 to 5.80, with an overall AAPC of -2.47.</p><p><strong>Conclusion: </strong>Males globally showed higher ASMR, whereas in the US, females had higher rates. While asthma incidence and prevalence increased in the US, global rates declined. Both the US and global populations experienced substantial reductions in asthma-related mortality, highlighting the need for targeted interventions and international collaboration.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1407-1417"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics associated with activities of daily living (ADL), instrumental activities of daily living (IADL), functional, or other activity limitation among United States adults with asthma.","authors":"David R Axon","doi":"10.1080/02770903.2025.2482993","DOIUrl":"10.1080/02770903.2025.2482993","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to explore the characteristics associated with having a limitation, which included any activities of daily living (ADL), instrumental activities of daily living (IADL), functional, or other activity limitations, among adults with asthma in the United States (US).</p><p><strong>Methods: </strong>This cross-sectional study included US adults (≥18 years) with asthma in the 2021 Medical Expenditure Panel Survey. A multivariable logistic regression model assessed the association between the following characteristics and the dependent variable (having a limitation, which included ADL, IADL, functional, or other activity limitation): age, sex, race, ethnicity, education, employment, income, marriage, exercise, smoking, pain, overall health, and mental health.</p><p><strong>Results: </strong>The sample included 2325 (limitation <i>n</i> = 940, no limitation <i>n</i> = 1385) US adults with asthma, which represented an estimated weighted population of 37 210 236 (limitation <i>n</i> = 11 104 087, no limitation <i>n</i> = 26 106 149). In this analysis, characteristics associated with having a limitation (versus no limitation) included: age ≥65 versus 18-39 years (odds ratio (OR)=6.6, 95% confidence interval (CI)=3.8-11.4), age 40-64 versus 18-39 years (OR = 2.4, 95% CI = 1.5-3.9), unemployed versus employed (OR = 2.6, 95% CI = 1.7-4.0), low versus middle/high income (OR = 1.5, 95% CI = 1.0-2.2), not married versus married (OR = 1.8, 95% CI = 1.2-2.7), smoker versus nonsmoker (OR = 3.0, 95% CI = 1.7-5.3), quite a bit/extreme versus little/moderate pain (OR = 2.8, 95% CI = 1.8-4.3), fair/poor versus good overall health (OR = 3.3, 95% CI = 2.0-5.3), and fair/poor versus excellent/very good overall health (OR = 6.3, 95% CI = 3.5-11.4).</p><p><strong>Conclusions: </strong>In conclusion, these findings offer some insight into having a limitation among US adults with asthma, although a future prospective study is needed to establish evidence of causality.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1399-1406"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of risk factors for severe acute pediatric asthma exacerbation in Quanzhou, Southern China.","authors":"Qionghua Chen, Jingyang Zheng, Chunyan Lin, Tianwen Zheng, Qiaoya Hong","doi":"10.1080/02770903.2025.2475457","DOIUrl":"10.1080/02770903.2025.2475457","url":null,"abstract":"<p><strong>Objective: </strong>To investigate risk factors associated with severe acute asthma attacks in children with asthma over six years of age.</p><p><strong>Methods: </strong>This retrospective study enrolled children aged over six years diagnosed with acute asthma exacerbation at the Department of Pulmonology, Quanzhou Children's Hospital, from January 2012 to September 2024. Data on the patients' clinical manifestations were compared between the mild to moderate and severe asthma attack groups.</p><p><strong>Results: </strong>The average age of the 261 patients was 8.03 ± 1.88 years. The patients were categorized into two groups based on attack severity: mild to moderate (<i>n</i> = 209) and severe (<i>n</i> = 52). Univariate analysis revealed significant differences between the two groups in terms of malnutrition, breastfeeding duration (over three and six months), eosinophil and neutrophil percentages, human rhinovirus (HRV) infection, mediastinal emphysema, and subcutaneous emphysema (<i>p</i> < 0.05). Logistic regression analysis revealed that children over six years of age hospitalized for asthma attacks were more likely to experience severe exacerbations if they had an elevated neutrophil % (OR = 1.040), HRV infection (OR = 5.655), malnutrition (OR = 5.051), or mediastinal emphysema (OR = 9.205). ROC analysis revealed that a neutrophil percentage threshold of 69.35 (the threshold value of neutrophil count over 6 years old is 1.6-8.3 × 10⁹/L) was diagnostically useful for severe asthma, with a sensitivity of 0.750, specificity of 0.617, and an area under the curve of 0.73.</p><p><strong>Conclusion: </strong>The level of neutrophils, history of HRV infection, malnutrition, and mediastinal emphysema are all independent risk factors for a severe acute asthma attack in children aged over six years. Management strategies for asthma should be expanded to focus on high-risk children in order to avoid severe attacks.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1324-1331"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediation analysis of gut microbiota and plasma metabolites in asthma pathogenesis using Mendelian randomization.","authors":"XuWen Zheng, JinNan Yin, Liang Zhao, YongJun Qian, Jin Xu","doi":"10.1080/02770903.2025.2478504","DOIUrl":"10.1080/02770903.2025.2478504","url":null,"abstract":"<p><strong>Objective: </strong>Asthma is a prevalent chronic respiratory condition with multifactorial pathogenesis. Emerging evidence suggests that gut microbiota and their metabolites influence asthma risk. This study explores the mediation effects of plasma metabolites between gut microbiota and asthma using Mendelian randomization (MR) analysis.</p><p><strong>Methods: </strong>Publicly available genome-wide association study (GWAS) data were analyzed, comprising 5,959 individuals for gut microbiota, 8,299 for plasma metabolites, and 543,586 (86,923 cases and 456,663 controls) for asthma outcomes. MR analyses were conducted to evaluate causal relationships between gut microbiota, plasma metabolites, and asthma. Mediation effects were assessed using the product of coefficients approach, and statistical significance was determined with Bonferroni correction.</p><p><strong>Results: </strong>The MR analysis identified 24 gut microbiomes and 88 plasma metabolites with suggestive associations with asthma. Notably, mediation analysis revealed that the phylum <i>Cyanobacteria</i> reduced asthma risk <i>via</i> the alpha-tocopherol to glycerol ratio (mediated proportion: 37.48%), while the species <i>UBA2922 sp900313925</i> and the order <i>Parachlamydiales</i> increased risk through arachidonate to linoleate (14.62%) and hypotaurine to taurine (29.36%) ratios, respectively.</p><p><strong>Conclusion: </strong>This study underscores the significant role of the gut microbiota-lung axis in asthma pathogenesis. By identifying specific gut microbiota and metabolite pathways, the findings pave the way for innovative biomarkers and therapeutic strategies targeting gut microbiota and its metabolites to manage and prevent asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1351-1363"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling asthma through single-cell RNA sequencing in understanding disease mechanisms.","authors":"Xingxing Yuan, Chaofan Li, Liuxin Yang, Jiawei Gao, Bingyu Wang, Zhuying Li","doi":"10.1080/02770903.2025.2472358","DOIUrl":"10.1080/02770903.2025.2472358","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the fundamental principles of single-cell RNA sequencing (scRNA-seq) and summarize its application in asthma research, aiming to enhance understanding of asthma pathophysiology and guide future research directions.</p><p><strong>Datasource: </strong>Recent advances and emerging research in scRNA-seq and its role in the pathogenesis of asthma.</p><p><strong>Study selections: </strong>This review incorporates studies that analyzed the heterogeneity of asthma cell types and their functional states using scRNA-seq, with particular emphasis on immune cells and airway remodeling. The selection of specific cell types and markers was based on their relevance to asthma pathogenesis, and we discuss the rationale for favoring certain scRNA-seq technologies in these investigations.</p><p><strong>Results: </strong>ScRNA-seq technology has provided insights into the key mechanisms underlying inflammation and airway remodeling in asthma. It has uncovered the diversity of immune cell subtypes and their specific roles in asthma pathogenesis, revealing critical pathways that contribute to disease progression. These findings offer a theoretical foundation for the development of targeted therapeutic strategies, paving the way for personalized medicine and improved patient outcomes.</p><p><strong>Conclusion: </strong>ScRNA-seq reveals the complex heterogeneity and functional roles of immune cells in asthma, offering key insights into disease mechanisms and the potential for targeted therapies. However, challenges remain, such as the need for further refinement of data integration methods and addressing the limited clinical applicability of current findings. Future research should focus on overcoming these limitations, improving cell type annotation, and expanding studies to include longitudinal and clinical data to better understand disease dynamics and therapy responses.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1257-1265"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}